MX2022007546A - Interferon-alfa-2 modificado que tiene inmunogenicidad reducida. - Google Patents

Interferon-alfa-2 modificado que tiene inmunogenicidad reducida.

Info

Publication number
MX2022007546A
MX2022007546A MX2022007546A MX2022007546A MX2022007546A MX 2022007546 A MX2022007546 A MX 2022007546A MX 2022007546 A MX2022007546 A MX 2022007546A MX 2022007546 A MX2022007546 A MX 2022007546A MX 2022007546 A MX2022007546 A MX 2022007546A
Authority
MX
Mexico
Prior art keywords
interferon
modified interferon
reduced immunogenicity
nucleic acid
present disclosure
Prior art date
Application number
MX2022007546A
Other languages
English (en)
Spanish (es)
Inventor
Marina Etcheverrigaray
Eduardo Federico Mufarrege
Sofía Inés Giorgetti
Groot Anne Searls De
William D Martin
Original Assignee
Epivax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epivax Inc filed Critical Epivax Inc
Publication of MX2022007546A publication Critical patent/MX2022007546A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2022007546A 2019-12-17 2020-12-16 Interferon-alfa-2 modificado que tiene inmunogenicidad reducida. MX2022007546A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ARP190103715A AR117715A1 (es) 2019-12-17 2019-12-17 Interferón hiperglicosilado con inmunogenicidad reducida
PCT/US2020/065246 WO2021126929A1 (en) 2019-12-17 2020-12-16 Modified interferon-alpha-2 having reduced immunogenicity

Publications (1)

Publication Number Publication Date
MX2022007546A true MX2022007546A (es) 2022-11-30

Family

ID=76478524

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007546A MX2022007546A (es) 2019-12-17 2020-12-16 Interferon-alfa-2 modificado que tiene inmunogenicidad reducida.

Country Status (7)

Country Link
US (1) US20230127506A1 (cg-RX-API-DMAC7.html)
EP (1) EP4076504A4 (cg-RX-API-DMAC7.html)
JP (1) JP7786010B2 (cg-RX-API-DMAC7.html)
AR (1) AR117715A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022011975A2 (cg-RX-API-DMAC7.html)
MX (1) MX2022007546A (cg-RX-API-DMAC7.html)
WO (1) WO2021126929A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240067691A1 (en) 2022-08-18 2024-02-29 Regeneron Pharmaceuticals, Inc. Interferon receptor agonists and uses thereof
KR20250048583A (ko) 2022-08-18 2025-04-09 리제너론 파아마슈티컬스, 인크. 인터페론 전구단백질 및 이의 용도
KR20260026098A (ko) 2023-05-12 2026-02-25 리제너론 파아마슈티컬스, 인크. 인터페론 수용체 길항제 및 이의 용도
CN116814595B (zh) * 2023-08-30 2023-11-28 江苏申基生物科技有限公司 一种腺苷脱氨酶突变体及其固定化
WO2026104336A1 (en) 2024-11-13 2026-05-21 F. Hoffmann-La Roche Ag Immunoconjugates

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
EP1379555A2 (en) * 2001-03-02 2004-01-14 MERCK PATENT GmbH Modified interferon alpha with reduced immunogenicity
MX2007001589A (es) * 2004-08-09 2007-08-02 Alios Biopharma Inc Variantes de polipeptido resistentes a proteasa, hiperglicosiladas sinteticas, formulaciones orales y metodos para utilizar las mismas.
KR20080026135A (ko) 2005-06-03 2008-03-24 암브룩스, 인코포레이티드 개선된 인간 인터페론 분자 및 이의 용도
JP5208733B2 (ja) 2005-06-29 2013-06-12 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 組換えインターフェロンα2(IFNα2)変異体
AR057215A1 (es) 2006-12-01 2007-11-21 Univ Nac Del Litoral Unl Proteina de fusion
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
CA2695543A1 (en) 2007-08-06 2009-02-12 Schering Corporation Gamma secretase modulators
PE20170908A1 (es) 2014-10-29 2017-07-12 Teva Pharmaceuticals Australia Pty Ltd VARIANTES DE INTERFERON a2b
AR102120A1 (es) * 2015-09-29 2017-02-08 Univ Nac Del Litoral Interferón modificado con inmunogenicidad reducida
JP7534215B2 (ja) 2018-01-24 2024-08-14 ベイジン パーカンズ オンコロジー カンパニー リミテッド サイトカイン融合タンパク質

Also Published As

Publication number Publication date
BR112022011975A2 (pt) 2022-08-30
WO2021126929A1 (en) 2021-06-24
EP4076504A4 (en) 2024-04-10
JP2023514659A (ja) 2023-04-07
AR117715A1 (es) 2021-08-25
JP7786010B2 (ja) 2025-12-16
EP4076504A1 (en) 2022-10-26
US20230127506A1 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
JP2023011697A (ja) 核酸産物およびその投与方法
ES3058577T3 (en) Conjugated hepcidin mimetics for use in treating of polycythemia vera
JP7199809B2 (ja) 核酸製品及びその投与方法
SA521430398B1 (ar) Ph20 تركيبة صيدلانية، تشمل متغير ودواء هيالورونيداز البشرى، للحقن تحت الجلد
ES2544573T3 (es) Inhibidores diméricos de afinidad elevada de PSD-95 y su uso para el tratamiento del daño cerebral isquémico y del dolor
ZA202208999B (en) Biased il2 muteins methods and compositions
NZ587105A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
PT99565B (pt) Processo para a preparacao de factores de crescimento de fibroblastos quimerico s
BR112022011975A2 (pt) Polipeptídeo de interferon-¿2 modificado, polipeptídeo gmop-interferon-¿2 modificado, ácido nucleico, plasmídeo, vetor, linha de célula, método para purificação do polipeptídeo de interferon-¿2 modificado, composição farmacêutica, método para uso de um ou mais dos polipeptídeos de interferon-¿2 modificados e método para tratar uma condição médica em um indivíduo
AU2005283025A1 (en) Muteins of fibroblast growth factor 21
PT2621515T (pt) Polipéptido quimérico de leptina de foca-ser humano com solubilidade aumentada
AU2018254410B2 (en) Optimization of enzyme replacement therapy for treatment of homocystinuria
CN110256575A (zh) 一种长效重组人生长激素融合蛋白及其工程细胞
NZ708990A (en) Method for activating helper t cell
WO2022256499A3 (en) Bcma targeting trispecific proteins and methods of use
CA2692358A1 (en) Recombinant human interferon-like proteins
EA021186B1 (ru) Композиции, включающие интерлейкин-1 и пептиды
MX2022008748A (es) Administración oral de péptidos.
PH12022553408A1 (en) Cytokine conjugates
EP0306870A2 (de) Gamma-Interferon-Derivate, Herstellungsverfahren, Vektoren dafür und Arzneimittel daraus
US20080200378A1 (en) KGF polypeptide compositions
KR20170024469A (ko) 상피세포 성장인자의 활성을 가지는 펩타이드 및 그의 용도
CN104292341B (zh) 一种凝血八因子融合蛋白及其制备方法和用途
AU2002326742A1 (en) KGF polypeptide compositions
PH12021552080A1 (en) Composition comprising albumin-coupled slit3 lrrd2 for prevention or treatment of muscle disease